Strides Pharma Science Ltd reports consolidated net profit of Rs. 93.23 crores in Q2 FY2025

Strides Pharma Science Limited has reported Consolidated financial results for the period ended September 30, 2024.

Financial Results (Q2 FY2025) - QoQ Comparison

The company has reported total income of Rs. 1229.521 crores during the period ended September 30, 2024 as compared to Rs. 1100.221 crores during the period ended June 30, 2024.

The company has posted net profit / (loss) of Rs. 93.232 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 70.202 crores for the period ended June 30, 2024.

The company has reported EPS of Rs. 10.12 for the period ended September 30, 2024 as compared to Rs. 7.62 for the period ended June 30, 2024.

Financials	Q2 FY2025	Q1 FY2025	% Change
Total Income	₹ 1229.521 crs	₹1100.221 crs	11.75%
Net Profit	₹93.232 crs	₹70.202 crs	32.81%
EPS	₹10.12	₹7.62	32.81%

Financial Results (Q2 FY2025) - YoY Comparison

The company has reported total income of Rs. 1229.521 crores during the period ended September 30, 2024 as compared to Rs.1035.275 crores during the period ended September 30, 2023.

The company has posted net profit / (loss) of Rs.93.232 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.-131.343 crores for the period ended September 30, 2023.

The company has reported EPS of Rs.10.12 for the period ended September 30, 2024 as compared to Rs.-14.54 for the period ended September 30, 2023.

Financials	Q2 FY2025	Q2 FY2024	% Change
Total Income	₹ 1229.521 crs	₹1035.275 crs	18.76%
Net Profit	₹93.232 crs	₹-131.343 crs	170.98%
EPS	₹10.12	₹-14.54	169.60%

Financial Results (Half Year Ended FY2025) - YoY Comparison

The company has reported total income of Rs.2329.742 crores during the 6 Months period ended September 30, 2024 as compared to Rs.1973.914 crores during the 6 Months period ended September 30, 2023.

The company has posted net profit / (loss) of Rs.163.434 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.-138.456 crores for the 6 Months period ended September 30, 2023.

The company has reported EPS of Rs.17.75 for the 6 Months period ended September 30, 2024 as compared to Rs.-15.33 for the 6 Months period ended September 30, 2023.

Financials	Half Year Ended FY2025	Half Year Ended FY2024	% Change
Total Income	₹2329.742 crs	₹1973.914 crs	18.03%
Net Profit	₹163.434 crs	₹-138.456 crs	218.04%
EPS	₹17.75	₹-15.33	215.79%

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 1534.65 as compared to the previous close of Rs. 1558.70. The total number of shares traded during the day was 35551 in over 2421 trades.

The stock hit an intraday high of Rs. 1620.00 and intraday low of 1526.85. The net turnover during the day was Rs. 55692554.00.

Source : Equity Bulls

Keywords

StridesPharmaScience Q2FY25 H1FY25 Q2FY2025 H1FY2025 ResultUpdate